Kraig Biocraft Laboratories (KBLB) Stock Price
Kraig Biocraft Laboratories Price
Revenue has compounded at 255.1% per year over the past 2 years to 401,620.00 USD. Kraig Biocraft Laboratories's net margin stands at -291.1%, up from -9,648.6% several years earlier. Over the past year Kraig Biocraft Laboratories shares have lost 3.4%.
Kraig Biocraft Laboratories stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Kraig Biocraft Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Kraig Biocraft Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Kraig Biocraft Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Kraig Biocraft Laboratories Price |
|---|---|
| 9/14/2026 | 0.08 USD |
| 9/13/2026 | 0.08 USD |
| 9/11/2026 | 0.08 USD |
| 9/10/2026 | 0.08 USD |
| 9/9/2026 | 0.08 USD |
| 9/8/2026 | 0.08 USD |
| 9/4/2026 | 0.08 USD |
| 9/3/2026 | 0.08 USD |
| 9/2/2026 | 0.08 USD |
| 9/1/2026 | 0.08 USD |
| 8/31/2026 | 0.08 USD |
| 8/30/2026 | 0.08 USD |
| 8/28/2026 | 0.09 USD |
| 8/27/2026 | 0.09 USD |
| 8/26/2026 | 0.09 USD |
| 8/25/2026 | 0.09 USD |
| 8/24/2026 | 0.09 USD |
| 8/21/2026 | 0.09 USD |
| 8/20/2026 | 0.09 USD |
| 8/19/2026 | 0.09 USD |
| 8/18/2026 | 0.09 USD |
| 8/17/2026 | 0.09 USD |
| 8/14/2026 | 0.09 USD |
| 8/13/2026 | 0.09 USD |
| 8/12/2026 | 0.09 USD |
| 8/11/2026 | 0.09 USD |
| 8/10/2026 | 0.09 USD |
| 8/7/2026 | 0.09 USD |
| 8/6/2026 | 0.09 USD |
| 8/5/2026 | 0.10 USD |
Kraig Biocraft Laboratories Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Kraig Biocraft Laboratories Income Statement, Balance Sheet, Cash Flow Statement
| EBITM USD |
|---|
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESB |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -1.00 | -2.00 | -2.00 | -2.00 | – | -2.00 | -4.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 |
| – | – | – | – | -1.00 | -2.00 | -3.00 | -2.00 | -1.00 | -2.00 | -4.00 | -8.00 | -3.00 | -3.00 | -3.00 | -3.00 |
| – | – | – | – | – | 100.00 | 50.00 | -33.33 | -50.00 | 100.00 | 100.00 | 100.00 | -62.50 | – | – | – |
| 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.82 | 0.82 | 0.84 | 0.85 | 0.93 | 1.03 | 1.04 | 1.04 | 1.08 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Kraig Biocraft Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Kraig Biocraft Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Kraig Biocraft Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Kraig Biocraft Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Kraig Biocraft Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Kraig Biocraft Laboratories stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Kraig Biocraft Laboratories Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Kraig Biocraft Laboratories business model & stock analysis
Kraig Biocraft Laboratories SWOT Analysis
Strengths
Kraig Biocraft Laboratories Inc has several key strengths that contribute to its competitive advantage in the industry. These strengths include:
- Strong Research and Development Capabilities: The company's ability to innovate and develop advanced technologies sets it apart from competitors.
- Pioneering Products: Kraig Biocraft Laboratories Inc is known for its groundbreaking products that have gained recognition and market traction.
- Strategic Partnerships: The company has established valuable partnerships with industry leaders, enabling access to resources, knowledge, and market reach.
- Strong Brand Reputation: Kraig Biocraft Laboratories Inc enjoys a positive brand image due to its commitment to quality and cutting-edge solutions.
Weaknesses
Despite its strengths, Kraig Biocraft Laboratories Inc also faces certain weaknesses that need to be addressed for sustained growth and success. These weaknesses include:
- Limited Financial Resources: The company's financial resources may restrict its ability to undertake large-scale projects or expand operations rapidly.
- Dependence on Key Customers: Kraig Biocraft Laboratories Inc relies heavily on a few major customers, which poses a risk if any customer reduces or terminates its business with the company.
- Regulatory Challenges: The regulatory environment in the industry can be complex and stringent, creating obstacles for product development and commercialization.
- Limited Global Presence: The company's geographical reach may hinder its access to new markets and potential customers.
Opportunities
Kraig Biocraft Laboratories Inc can leverage various opportunities in the market to further enhance its business and create growth prospects. These opportunities include:
- Increasing Demand for Advanced Textile Solutions: There is a growing demand for innovative textiles with enhanced properties, presenting an opportunity for the company to expand its product portfolio.
- Emerging Markets: Expansion into emerging markets with untapped potential can provide Kraig Biocraft Laboratories Inc with access to new customer segments and revenue streams.
- Technological Advancements: The rapid pace of technological advancements offers the company opportunities to develop and commercialize new, cutting-edge products.
- Green and Sustainable Solutions: The focus on sustainability in the textile industry opens opportunities for Kraig Biocraft Laboratories Inc to offer eco-friendly alternatives.
Threats
Kraig Biocraft Laboratories Inc operates in a dynamic market landscape that poses certain threats to its business operations and growth. These threats include:
- Intense Competition: The industry is highly competitive, with numerous players vying for market share, which increases the risk of price wars and reduced profit margins.
- Economic Factors: Economic downturns or fluctuations can impact consumer spending and demand for the company's products.
- Intellectual Property Risks: The risk of intellectual property infringement or theft could result in loss of competitive advantage and financial damages.
- Changing Consumer Preferences: Shifts in consumer preferences towards alternative materials or technologies could negatively impact demand for Kraig Biocraft Laboratories Inc's products.
Kraig Biocraft Laboratories Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Kraig Biocraft Laboratories Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Kraig Biocraft Laboratories historical P/E ratio, EBIT multiple, and P/S ratio
Kraig Biocraft Laboratories annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Kraig Biocraft Laboratories's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Kraig Biocraft Laboratories's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Kraig Biocraft Laboratories's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Kraig Biocraft Laboratories shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Kraig Biocraft Laboratories stock splits
Since 2009, a total of 10 shares have been converted from one Kraig Biocraft Laboratories share.
Kraig Biocraft Laboratories shareholder structure
| % | Name |
|---|---|
19.42247% | |
0.47252% | |
0.00482% |
Kraig Biocraft Laboratories Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
24.30% | SEC ↗ |
Kraig Biocraft Laboratories Executives and Management Board
3 members · avg. age 56 · 0 % women
Mr. Kenneth Le (60)
President of Prodigy Textiles
752,450.00 USD
Mr. Kim Thompson (63)
President, Chief Executive Officer, Chief Financial Officer, Director · since 2006
Mr. Jonathan Rice (45)
Chief Operating Officer
Frequently asked questions about Kraig Biocraft Laboratories
The business model of Kraig Biocraft Laboratories Inc is centered around the development and commercialization of innovative recombinant spider silk technologies. The company specializes in genetic engineering techniques to create spider silk-based biomaterials that have a wide range of applications in various industries, including textiles, defense, and medical. Kraig Biocraft Laboratories Inc aims to leverage the unique properties of spider silk, such as its strength and elasticity, to revolutionize existing materials and drive advancements in multiple sectors. Through ongoing research and development efforts, the company strives to create sustainable and high-performance materials that can meet the evolving demands of various markets.
Kraig Biocraft Laboratories Inc primarily operates in the biotechnology industry.
Some of the main competitors of Kraig Biocraft Laboratories Inc in the market include companies such as Spiber Inc, Bolt Threads Inc, and AMSilk GmbH.
Kraig Biocraft Laboratories Inc is a leading biotechnology company specializing in the development of genetically engineered spider silk materials. Established in 2006, the company has dedicated extensive research and development efforts in harnessing the extraordinary properties of spider silk. Kraig Biocraft Laboratories Inc has made significant advancements in genetic engineering techniques to produce spider silk through silkworms, resulting in scalable and cost-effective production. The company's innovative approach has attracted collaborations with various government agencies and private sector partners. Kraig Biocraft Laboratories Inc continues to drive advancements in the field of biomaterials with a strong commitment to sustainability and commercial viability.
Kraig Biocraft Laboratories Inc has achieved several significant milestones. Firstly, the company successfully developed genetically engineered silkworms capable of producing spider silk, a strong and durable material with various applications. Additionally, Kraig Biocraft Laboratories Inc garnered recognition for its innovative technology and received grants and funding for further research and development. Moreover, the company established strategic partnerships and collaborations to accelerate its commercialization efforts. These milestones demonstrate Kraig Biocraft Laboratories Inc's commitment to revolutionizing textiles and materials through its groundbreaking advancements in genetic engineering and silk production.
Kraig Biocraft Laboratories Inc, a leading biotechnology company, operates primarily in the United States. With its headquarters located in Ann Arbor, Michigan, the company focuses on developing innovative materials through genetic engineering. As of now, Kraig Biocraft Laboratories Inc has not expanded its presence internationally and primarily serves its customers and stakeholders within the United States. With a strong commitment to advancements in biotechnology, the company continues to explore potential opportunities for expansion and collaboration across different regions in the future.
Kraig Biocraft Laboratories Inc is a company that values innovation, sustainability, and collaboration. The company is committed to developing and commercializing next-generation materials and technologies in the field of biotechnology. Kraig Biocraft Laboratories Inc follows a corporate philosophy that focuses on pushing the boundaries of science and research to drive positive change in the world. With its expertise in genetic engineering and biotechnology, the company aims to create advanced spider silk materials with unique properties, revolutionizing industries such as textiles and medical applications. Kraig Biocraft Laboratories Inc strives to be a leader in the biotech industry, delivering groundbreaking solutions for a more sustainable future.
Converted at the current exchange rate, the Kraig Biocraft Laboratories share trades at 0.07 EUR (0.08 USD).
Kraig Biocraft Laboratories Inc. is a leading biotechnology company specializing in the development of spider silk products. The company was founded in Michigan in 2006 and has since built an excellent reputation in the industry. The business model of Kraig Biocraft Laboratories Inc. is primarily based on the production of thread materials from spider silk proteins. The spider silk proteins are produced using a biotechnological process that involves genetically modified silkworms whose genomes contain individual genes originally derived from spiders. Using this method, Kraig Biocraft Laboratories Inc. is able to produce fibers that have better strength, elasticity, and durability than conventional synthetic fibers. The company offers its products in various sectors, including military and law enforcement, biomedicine, and fashion. In the military and law enforcement sector, Kraig Biocraft Laboratories Inc. develops fiber products specifically designed for use in tactical equipment and protective clothing. The products of this company are more resistant to bullets, knives, cuts, and stabs than conventional protective clothing. The biomedicine sector is another major pillar of the company. Kraig Biocraft Laboratories Inc. has developed a method for producing artificial silk threads that can be used in medicine. These threads can be used as scaffolds for tissue regeneration. Furthermore, the company is able to produce silk proteins that can help prevent the rejection of medical devices from the body, increasing the effectiveness of the treatment. The fashion industry is another important market for Kraig Biocraft Laboratories Inc. The company hopes to start a revolution in the fashion industry by producing garments that are not only durable and resistant but also comfortable to wear and environmentally friendly. The products offered are natural and fully biodegradable, meeting the needs of environmentally conscious individuals who prefer materials made from natural resources. The company is working to fully harness the potential of silk fiber and develop a wider range of products that can be used by various industries. It has also formed partnerships with other leading companies around the world to expand business opportunities and drive growth. Kraig Biocraft Laboratories Inc. is an innovative company that represents a turning point in the textile industry. It offers revolutionary products that are not only made based on the latest technologies but also make a positive contribution to the environment. The company aims to change market and industry standards and create a better future for its customers.
The revenue cannot currently be calculated for Kraig Biocraft Laboratories.
The profit cannot currently be calculated for Kraig Biocraft Laboratories.
The P/E ratio cannot be calculated for Kraig Biocraft Laboratories at the moment.
The P/S cannot be calculated for Kraig Biocraft Laboratories currently.
The Eulerpool Quality Score for Kraig Biocraft Laboratories is 2/10.
The ISIN of Kraig Biocraft Laboratories is US50075W1045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Kraig Biocraft Laboratories is A0YJA0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Kraig Biocraft Laboratories is KBLB. The ticker symbol is used to trade Kraig Biocraft Laboratories shares on the stock exchange.
Kraig Biocraft Laboratories paid dividends every year for the past 0 years.
Kraig Biocraft Laboratories is assigned to the 'Commodities' sector.
The dividends of Kraig Biocraft Laboratories are distributed in USD.
Kraig Biocraft Laboratories stock
Kraig Biocraft Laboratories Peer Group
Kraig Biocraft Laboratories Ticker
Kraig Biocraft Laboratories FIGI
All fundamentals and in-depth analysis of Kraig Biocraft Laboratories
Our stock analysis for Kraig Biocraft Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kraig Biocraft Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.